The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review
Abstract
Introduction: Treatment is generally not available for drug-induced liver injury (DILI) patients except in some specific circumstances. The management of DILI is based on the withdrawal of the responsible drug and monitoring the patients and only a few patients need to be referred to a transplant center. Some studies on the role of ursodeoxycholic acid (UDCA) in DILI have been published. The aim of this study was to perform a systematic review of the role of UDCA in the treatment and prevention of DILI. Methods: A search was undertaken in PubMed, with the key words ursodeoxycholic acid, drug-induced liver injury and hepatotoxicity following the PRISMA guidelines. Results: A total of 33 publications were identified: 25 case reports and 8 case series. In 18 of the 25 cases reports (22 patients), authors reported improvement of liver injury associated with UDCA therapy whereas 7 case reports did not show clinical or biochemical improvement after UDCA treatment. There were 4 studies evaluating the role of UDCA in the treatment of DILI, three prospective (one being a clinical trial) and one retrospective studies. Three studies observed liver profile improvements associated with UDCA. In addition, four studies evaluated UDCA in the prevention of DILI: one pilot study, two randomized clinical trials (RCT) and one retrospective study. Three of these studies observed a lower percentage of patients with an increase in transaminases in the groups that used UDCA for DILI prevention. Conclusion: According to available data UDCA seems to have some benefits in the treatment and prevention of DILI. However, the design of the published studies does not allow a firm conclusion to be drawn on the efficacy of UDCA in DILI. A well designed RCT to evaluate the role of UDCA in DILI is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small case series have shown improvement in liver biochemistries with varying doses of UDCA”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [81]
In the citing paper
“however, multiple meta-analyses have shown inconsistent benefit of UDCA in the resolution of DILI.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“, 2020) (4 points, possible and 6 points, probable association to the drug, respectively) and in one case Naranjo scale (Naranjo et al., 1981) was applied (Agca et al.”
MethodHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 5×
“Ursodeoxycholic acid (UDCA) is recommended by liver societies for the treatment of patients with primary biliary cholangitis (PBC) (Hirschfield et al., 2017; Hirschfield et al., 2018; Lindor et al., 2019).”
BackgroundInfluentialEASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 4×
“12:744488. doi: 10.3389/fphar.2021.744488 Abbreviations: AAS, androgenic anabolic steroid; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLD, chronic liver disease; DILI, drug-induced liver injury; DILIN, Drug-Induced Liver Injury Network; ERCP, endoscopic retrograde cholan…”
BackgroundInfluentialACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“UDCA seems to prevent apoptosis in hepatocytes at the mitochondria level and protect cholangiocytes against the toxic action of endogenous bile acids (Beuers, 2006; Beuers et al., 2015).”
BackgroundHirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362 · cited 4×
“12:744488. doi: 10.3389/fphar.2021.744488 Abbreviations: AAS, androgenic anabolic steroid; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLD, chronic liver disease; DILI, drug-induced liver injury; DILIN, Drug-Induced Liver Injury Network; ERCP, endoscopic retrograde cholan…”
BackgroundInfluential
Research works printed but not linked: 56
- Abeles, 2020, Androgenic Anabolic Steroid-Induced Liver Injury: Two Case Reports Assessed for Causality by the Updated Roussel Uclaf Causality Assessment Method (RUCAM) Score and a Comprehensive Review of the Literature, BMJ Open Gastroenterol., 7, 7, 10.1136/bmjgast-2020-000549 · DOI
- Agca, 2004, Ursodeoxycholic Acid for Terbinafine-Induced Toxic Hepatitis, Ann. Pharmacother., 38, 1088, 10.1345/aph.1D420 · doi:10.1345/aph.1d420
- Ahmed, 2020, Delayed Presentation of Drug-Induced Hepatic Injury, Cureus, 12, e9713, 10.7759/cureus.9713 · doi:10.7759/cureus.9713
- Aithal, 2011, Case Definition and Phenotype Standardization in Drug-Induced Liver Injury, Clin. Pharmacol. Ther., 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
- Alhumaidha, 2014, Protective Effects of Ursodeoxycholic Acid on Ceftriaxone-Induced Hepatic Injury in Rats, Bull. Fac. Pharm. Cairo Univ., 52, 45, 10.1016/j.bfopcu.2014.02.002 · doi:10.1016/j.bfopcu.2014.02.002
- Ali, 2020, Ursodeoxycholic Acid Abrogates Gentamicin-Induced Hepatotoxicity in Rats: Role of NF-κB-p65/TNF-α, Bax/Bcl-xl/Caspase-3, and eNOS/iNOS Pathways, Life Sci., 254, 117760, 10.1016/j.lfs.2020.117760 · DOI
- Amaral, 2007, p53 Is a Key Molecular Target of Ursodeoxycholic Acid in Regulating Apoptosis, J. Biol. Chem., 282, 34250, 10.1074/jbc.M704075200 · DOI
- Asgarshirazi, 2015, Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: A Pilot Study, Acta Med. Iran, 53, 351
- Ashby, 2018, Review Article: Therapeutic Bile Acids and the Risks for Hepatotoxicity, Aliment. Pharmacol. Ther., 47, 1623, 10.1111/apt.14678 · DOI
- Bandiera, 2015, miR-122--a Key Factor and Therapeutic Target in Liver Disease, J. Hepatol., 62, 448, 10.1016/j.jhep.2014.10.004 · DOI · Paper page
- Bordbar, 2018, Effect of Ursodeoxycholic Acid and Vitamin E in the Prevention of Liver Injury from Methotrexate in Pediatric Leukemia, Turk J. Gastroenterol., 29, 203, 10.5152/tjg.2018.17521 · doi:10.5152/tjg.2018.17521
- Castro, 2005, A Distinct Microarray Gene Expression Profile in Primary Rat Hepatocytes Incubated with Ursodeoxycholic Acid, J. Hepatol., 42, 897, 10.1016/j.jhep.2005.01.026 · DOI
- Chawla, 2000, Rapidly Progressive Cholestasis: An Unusual Reaction to Amoxicillin/clavulanic Acid Therapy in a Child, J. Pediatr., 136, 121, 10.1016/S0022-3476(00)90064-7 · DOI
- Chen, 2011, The Protective Effects of Ursodeoxycholic Acid on Isoniazid Plus Rifampicin Induced Liver Injury in Mice, Eur. J. Pharmacol., 659, 53, 10.1016/j.ejphar.2011.03.007 · DOI
- Cicognani, 1996, Flutamide-induced Toxic Hepatitis. Potential Utility of Ursodeoxycholic Acid Administration in Toxic Hepatitis, Dig. Dis. Sci., 41, 2219, 10.1007/BF02071403 · DOI
- Danan, 1993, Causality Assessment of Adverse Reactions to Drugs--I. A Novel Method Based on the Conclusions of International Consensus Meetings: Application to Drug-Induced Liver Injuries, J. Clin. Epidemiol., 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- El Khoury, 2017, Severe Cholestasis and Bile Cast Nephropathy Induced by Anabolic Steroids Successfully Treated with Plasma Exchange, Case Rep. Med., 2017, 4296474, 10.1155/2017/4296474 · doi:10.1155/2017/4296474
- Fernandes, 2019, Kratom-Induced Cholestatic Liver Injury and its Conservative Management, J. Investig. Med. High Impact Case Rep., 7, 2324709619836138, 10.1177/2324709619836138 · DOI
- Gallelli, 2009, Hepatotoxicity Induced by Methimazole in a Previously Healthy Patient, Curr. Drug Saf., 4, 204, 10.2174/157488609789006912 · DOI
- Goossens, 2013, Severe Immune-Mediated Drug-Induced Liver Injury Linked to Ibandronate: A Case Report, J. Hepatol., 59, 1139, 10.1016/j.jhep.2013.06.003 · DOI
- Ito, 2014, Combined Use of Ursodeoxycholic Acid and Bosentan Prevents Liver Toxicity Caused by Endothelin Receptor Antagonist Bosentan Monotherapy: Two Case Reports, J. Med. Case Rep., 8, 250, 10.1186/1752-1947-8-250 · DOI
- Jorge, 2005, Hepatotoxicity Associated with the Ingestion of Centella asiatica, Rev. Esp Enferm Dig., 97, 115, 10.4321/S1130-01082005000200006 · DOI
- Katsinelos, 2000, Ursodeoxycholic Acid (UDCA) for the Treatment of Amoxycillin-Clavulanate Potassium (Augmentin)-Induced Intra-hepatic Cholestasis: Report of Two Cases, Eur. J. Gastroenterol. Hepatol., 12, 365, 10.1097/00042737-200012030-00017 · DOI
- Kim, 2019, Ursodeoxycholic Acid Exerts Hepatoprotective Effects by Regulating Amino Acid, Flavonoid, and Fatty Acid Metabolic Pathways, Metabolomics, 15, 30, 10.1007/s11306-019-1494-5 · DOI
- Kojima, 2002, Clinical Utility of Ursodeoxycholic Acid in Preventing Flutamide-Induced Hepatopathy in Patients with Prostate Cancer: A Preliminary Study, Int. J. Urol., 9, 42, 10.1046/j.1442-2042.2002.00412.x · doi:10.1046/j.1442-2042.2002.00412.x
- Krishnan, 2009, Prolonged Intrahepatic Cholestasis and Renal Failure Secondary to Anabolic Androgenic Steroid-Enriched Dietary Supplements, J. Clin. Gastroenterol., 43, 672, 10.1097/MCG.0b013e318188be6d · DOI
- Kurokawa, 2019, Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma, Intern. Med., 58, 3283, 10.2169/internalmedicine.2591-18 · DOI
- Lang, 2019, Ursodeoxycholic Acid Attenuates Hepatotoxicity of Multidrug Treatment of Mycobacterial Infections: A Prospective Pilot Study, Int. J. Mycobacteriol, 8, 89, 10.4103/ijmy.ijmy_159_18 · DOI · Paper page
- Lapenna, 2002, Antioxidant Properties of Ursodeoxycholic Acid, Biochem. Pharmacol., 64, 1661, 10.1016/S0006-2952(02)01391-6 · DOI
- Lee, 2017, Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches, Clin. Transl Sci., 10, 163, 10.1111/cts.12425 · DOI
- Li, 2019, Stevens-Johnson Syndrome and Acute Vanishing Bile Duct Syndrome after the Use of Amoxicillin and Naproxen in a Child, J. Int. Med. Res., 47, 4537, 10.1177/0300060519868594 · DOI
- Li, 2020, Ursodeoxycholic Acid Protects against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway, Front. Pharmacol., 11, 594496, 10.3389/fphar.2020.594496 · DOI
- Lindor, 2009, High-dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis, Hepatology, 50, 808, 10.1002/hep.23082 · DOI · Paper page
- Ljubuncic, 2000, Ursodeoxycholic Acid Suppresses Extent of Lipid Peroxidation in Diseased Liver in Experimental Cholestatic Liver Disease, Dig. Dis. Sci., 45, 1921, 10.1023/A:1005615306596 · DOI
- Miura, 2001, Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-kappaB-dependent Transcription by Ursodeoxycholic Acid, J. Biol. Chem., 276, 47371, 10.1074/jbc.M107098200 · DOI
- Mohammed Saif, 2012, Hepatoprotective Efficacy of Ursodeoxycholic Acid in Pediatrics Acute Lymphoblastic Leukemia, Pediatr. Hematol. Oncol., 29, 627, 10.3109/08880018.2012.713083 · DOI
- Neeman, 2019, Acute Liver Injury Leading to Death in the Setting of Brentuximab Vedotin Monotherapy, Leuk. Lymphoma, 60, 2283, 10.1080/10428194.2019.1579321 · doi:10.1080/10428194.2019.1579321
- O’Brien, 1996, Drug-induced Vanishing Bile Duct Syndrome: Response to Ursodiol, Am. J. Gastroenterol., 91, 1456
- Onishi, 2020, Ursodeoxycholic Acid and Bezafibrate Were Useful for Steroid-Refractory, Immune-Related Hepatitis: a Case Report, J. Med. Case Rep., 14, 230, 10.1186/s13256-020-02541-3 · DOI
- Paumgartner, 2004, Mechanisms of Action and Therapeutic Efficacy of Ursodeoxycholic Acid in Cholestatic Liver Disease, Clin. Liver Dis., 8, 67, 10.1016/S1089-3261(03)00135-1 · DOI · Paper page
- Piotrowicz, 1995, Ursodeoxycholic Acid for the Treatment of Flucloxacillin-Associated Cholestasis, J. Hepatol., 22, 119, 10.1016/0168-8278(95)80272-X · DOI
- 2006, Current Trends in BSEP Inhibition and Perturbation to Bile Acid Homeostasis as Mechanisms of Drug-Induced Liver Injury, 2006
- Reuben, 2016, Outcomes in Adults with Acute Liver Failure between 1998 and 2013: An Observational Cohort Study, Ann. Intern. Med., 164, 724, 10.7326/M15-2211 · DOI · Paper page
- Rudic, 2012, Ursodeoxycholic Acid for Primary Biliary Cirrhosis, Cochrane Database Syst. Rev., 12, CD000551, 10.1002/14651858.cd000551.pub3 · DOI · Paper page
- Saito, 2016, Effectiveness of Hepatoprotective Drugs for Anti-tuberculosis Drug-Induced Hepatotoxicity: A Retrospective Analysis, BMC Infect. Dis., 16, 668, 10.1186/s12879-016-2000-6 · doi:10.1186/s12879-016-2000-6
- Salmon, 2001, Ursodeoxycholic Acid and Prevention of Tacrine-Induced Hepatotoxicity: a Pilot Study, Therapie, 56, 29
- Sánchez-Osorio, 2008, Anabolic-androgenic Steroids and Liver Injury, Liver Int., 28, 278, 10.1111/j.1478-3231.2007.01579.x · DOI
- Singh, 1996, Extreme Hyperbilirubinemia Associated with the Use of Anabolic Steroids, Health/nutritional Supplements, and Ethanol: Response to Ursodeoxycholic Acid Treatment, Am. J. Gastroenterol., 91, 783
- Smith, 2005, Vanishing Bile Duct Syndrome: Amoxicillin-Clavulanic Acid Associated Intra-hepatic Cholestasis Responsive to Ursodeoxycholic Acid, J. Pediatr. Gastroenterol. Nutr., 41, 469, 10.1097/01.mpg.0000178086.44155.73 · DOI
- Stępień, 2015, Severe Intrahepatic Cholestasis and Liver Failure after Stanozolol Usage - and Review of the Literature, Clin. Exp. Hepatol., 1, 30, 10.5114/ceh.2015.51376 · doi:10.5114/ceh.2015.51376
- Stine, 2016, Current and Future Directions in the Treatment and Prevention of Drug-Induced Liver Injury: A Systematic Review, Expert Rev. Gastroenterol. Hepatol., 10, 517, 10.1586/17474124.2016.1127756 · DOI · Paper page
- Studniarz, 2012, Amoxicillin/clavulanic Acid-Induced Cholestatic Liver Injury after Pediatric Liver Transplantation, Ann. Transpl., 17, 128, 10.12659/aot.882646 · DOI
- Tejedor-Tejada, 2019, Hepatobiliary and Pancreatic: Sertraline-Induced Vanishing Bile Duct Syndrome Treated with Plasmapheresis, J. Gastroenterol. Hepatol., 34, 488, 10.1111/jgh.14503 · doi:10.1111/jgh.14503
- Uraz, 2008, Role of Ursodeoxycholic Acid in Prevention of Methotrexate-Induced Liver Toxicity, Dig. Dis. Sci., 53, 1071, 10.1007/s10620-007-9949-3 · DOI
- Vincent, 2014, Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players, Curr. Pathobiol Rep., 2, 109, 10.1007/s40139-014-0049-8 · DOI
- Wree, 2011, Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury, Digestion, 84, 54, 10.1159/000322298 · DOI · Paper page
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Björnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., et al. (2023) · Liver International · doi:10.1111/liv.15378 · Cited by 69
Self-citationThe contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Metadata
- Authors
- Robles-Díaz, M., Nezic, L., Vujic-Aleksic, V., & Björnsson, E. S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-10-27
- Volume
- 12
- ISSN
- 1663-9812
- Cited by
- 49
- References
- 9
- Funders
- Instituto de Salud Carlos III
- Consejería de Salud y Familias, Junta de Andalucía
- Agencia Española de Medicamentos y Productos Sanitarios
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- European Cooperation in Science and Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.